Cor Lieftink

6.0k citations

48 papers · 1.7k indexed · h-index 21

Impact in

Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
Molecular Biology top 10%
- Protein Tyrosine Phosphatases
- Epigenetics and DNA Methylation
- Melanoma and MAPK Pathways
- CRISPR and Genetic Engineering
- RNA modifications and cancer

Papers in ⓘ

Oncology 16
- Cancer-related Molecular Pathways 8
Aging 1

Co-authors: René Bernards (24 shared papers)Roderick L. Beijersbergen (42 shared papers)Cun Wang (6 shared papers)Bastiaan Evers (5 shared papers)Alberto Bardelli (3 shared papers)Sara Mainardi (3 shared papers)Liqin Wang (7 shared papers)Astrid Bosma (3 shared papers)
Journals: Cell Reports (4 papers)Oncotarget (3 papers)Nucleic Acids Research (3 papers)Molecular Cancer Therapeutics (3 papers)Life Science Alliance (2 papers)
Partner nations: Netherlands China United States

In The Last Decade

Cor Lieftink

47 papers receiving 1.6k citations

Peers

Countries citing papers authored by Cor Lieftink

Since Specialization

Citations

This map shows the geographic impact of Cor Lieftink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cor Lieftink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cor Lieftink more than expected).

Fields of papers citing papers by Cor Lieftink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cor Lieftink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cor Lieftink. The network helps show where Cor Lieftink may publish in the future.

Co-authors

The 25 scholars most cited alongside Cor Lieftink, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Cor Lieftink Line = papers co-authored together Cor Lieftink links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo Nature Medicine ·Sara Mainardi, Antonio Mulero‐Sánchez, Anirudh Prahallad, Giovanni Germano, Astrid Bosma, Paul Krimpenfort, Cor Lieftink, Jeffrey Steinberg, Niels de Wit, Samuel Gonçalves-Ribeiro, Ernest Nadal, Alberto Bardelli, Alberto Villanueva, René Bernards	2018	226
2	High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer Cell Reports ·Liqin Wang, Rodrigo Leite de Oliveira, Cun Wang, João M. Fernandes Neto, Sara Mainardi, Bastiaan Evers, Cor Lieftink, Ben Morris, Fleur Jochems, Lisa Willemsen, Roderick L. Beijersbergen, René Bernards	2017	163
3	A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer eLife ·Haojie Jin, Siying Wang, Esther A. Zaal, Cun Wang, Hai-Qiu Wu, Astrid Bosma, Fleur Jochems, Nikita Isima, Guang‐Zhi Jin, Cor Lieftink, Roderick L. Beijersbergen, Celia R. Berkers, Wenxin Qin, René Bernards	2020	137
4	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs Cell Reports ·Anirudh Prahallad, Guus J.J.E. Heynen, Giovanni Germano, Stefan M. Willems, Bastiaan Evers, Loredana Vecchione, Valentina Gambino, Cor Lieftink, Roderick L. Beijersbergen, Federica Di Nicolantonio, Alberto Bardelli, René Bernards	2015	114
5	RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells Cell Reports ·Simona Lamba, Mariangela Russo, Chong Sun, Luca Lazzari, Carlotta Cancelliere, Wipawadee Grernrum, Cor Lieftink, René Bernards, Federica Di Nicolantonio, Alberto Bardelli	2014	87
6	CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma Gut ·Cun Wang, Hui Wang, Cor Lieftink, Aimée du Chatinier, Dongmei Gao, Guang‐Zhi Jin, Haojie Jin, Roderick L. Beijersbergen, Wenxin Qin, René Bernards	2019	83
7	ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors Oncogene ·Katrien Berns, Joseph J. Caumanns, E. Marielle Hijmans, Annemiek M.C. Gennissen, Tesa Severson, Bastiaan Evers, G. Bea A. Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L. Beijersbergen, Hiroaki Itamochi, Ate G.J. van der Zee, Steven de Jong, René Bernards	2018	77
8	Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer Journal of Hepatology ·Cun Wang, Haojie Jin, Dongmei Gao, Cor Lieftink, Bastiaan Evers, Guang‐Zhi Jin, Xue Zheng, Liqin Wang, Roderick L. Beijersbergen, Wenxin Qin, René Bernards	2018	73
9	FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma Clinical Cancer Research ·Koos Koole, Diede Brunen, Pauline M.W. van Kempen, Rob Noorlag, Remco de Bree, Cor Lieftink, Robert J.J. van Es, René Bernards, Stefan M. Willems	2016	69
10	A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma European Urology ·Liqin Wang, Tonći Šuštić, Rodrigo Leite de Oliveira, Cor Lieftink, Pasi Halonen, Marieke van de Ven, Roderick L. Beijersbergen, Michel M. van den Heuvel, René Bernards, Michiel S. van der Heijden	2017	63
11	TRIM28 Is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming Stem Cells ·Denise C. Miles, Nienke A. de Vries, Santiago Gisler, Cor Lieftink, Waseem Akhtar, Ewa Gogola, Inka Pawlitzky, Danielle Hulsman, Ellen Tanger, Martijn Koppens, Roderick L. Beijersbergen, Maarten van Lohuizen	2016	46
12	Identification of signalling cascades involved in red blood cell shrinkage and vesiculation Bioscience Reports ·Elena Kostova, Boukje M. Beuger, Thomas R. Klei, Pasi Halonen, Cor Lieftink, Roderick L. Beijersbergen, Timo K. van den Berg, Robin van Bruggen	2015	34
13	Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R Molecular Cancer Therapeutics ·Klaas de Lint, Jos B. Poell, Hayssam Soueidan, Katarzyna Jastrzebski, Jordi Vidal Rodriguez, Cor Lieftink, Lodewyk F.A. Wessels, Roderick L. Beijersbergen	2016	33
14	A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers Genome Medicine ·Tonći Šuštić, Sake van Wageningen, Evert Bosdriesz, Robert J. D. Reid, John Dittmar, Cor Lieftink, Roderick L. Beijersbergen, Lodewyk F.A. Wessels, Rodney Rothstein, René Bernards	2018	32
15	Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities The Journal of Experimental Medicine ·Michela Serresi, Bjørn Siteur, Danielle Hulsman, Matthias Jürgen Schmitt, Cor Lieftink, Ben Morris, Matteo Cesaroni, Natalie Proost, Roderick L. Beijersbergen, Maarten van Lohuizen, Gaetano Gargiulo	2018	31
16	Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition Cell Reports ·Patrícia A. Possik, Judith Müller, Carmen Gerlach, Juliana C.N. Kenski, Xinyao Huang, Aida Shahrabi, Oscar Krijgsman, Ji‐Ying Song, Marjon A. Smit, Bram Gerritsen, Cor Lieftink, Kristel Kemper, Magali Michaut, Roderick L. Beijersbergen, Lodewyk F.A. Wessels, Ton N. Schumacher, Daniel S. Peeper	2014	31
17	Aurora A, MCAK, and Kif18b promote Eg5-independent spindle formation Chromosoma ·Roy G. H. P. van Heesbeen, Jonne A. Raaijmakers, Marvin E. Tanenbaum, Vincentius A. Halim, Daphne Lelieveld, Cor Lieftink, Albert J. R. Heck, David A. Egan, René H. Medema	2016	30
18	Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity Oncotarget ·Amy J.C. Dohmen, Xiaohang Qiao, Anja Duursma, Ruud H. Wijdeven, Cor Lieftink, Floor Hageman, Ben Morris, Pasi Halonen, Conchita Vens, Michiel W. M. van den Brekel, Huib Ovaa, Jacques Neefjes, Charlotte L. Zuur	2017	28
19	PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma Molecular Cancer Therapeutics ·Diede Brunen, Romy C. de Vries, Cor Lieftink, Roderick L. Beijersbergen, René Bernards	2018	27
20	Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer Genome Medicine ·Yuchen Guo, Jun Wang, Bente Benedict, Chen Yang, Frank van Gemert, Xuhui Ma, Dongmei Gao, Hui Wang, Shu Zhang, Cor Lieftink, Roderick L. Beijersbergen, Hein te Riele, Xiaohang Qiao, Qiang Gao, Chong Sun, Wenxin Qin, René Bernards, Cun Wang	2021	26

About Cor Lieftink

Cor Lieftink is a scholar working on Oncology, Aging, Molecular Biology, Cancer Research and Pathology and Forensic Medicine, having authored 48 papers that have together received 1.7k indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (8 papers), Cancer-related Molecular Pathways (8 papers), DNA Repair Mechanisms (7 papers), Cancer Mechanisms and Therapy (6 papers), Protein Degradation and Inhibitors (5 papers), Melanoma and MAPK Pathways (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Genomics and Chromatin Dynamics (5 papers). The work is most often cited by research in Cancer Research (318 citations), Molecular Biology (1.2k citations), Oncology (484 citations), Immunology (237 citations) and Aging (18 citations). Cor Lieftink has collaborated with scholars based in Netherlands, China and United States. Frequent co-authors include René Bernards, Roderick L. Beijersbergen, Cun Wang, Bastiaan Evers, Alberto Bardelli, Sara Mainardi, Liqin Wang, Astrid Bosma, Wenxin Qin and Giovanni Germano. Their work appears in journals such as Cell Reports, Oncotarget, Nucleic Acids Research, Molecular Cancer Therapeutics and Life Science Alliance.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact